WINDTREE THERAPEUTICS INC (WINT) Stock Price & Overview
NASDAQ:WINT • US97382D6004
Current stock price
The current stock price of WINT is 0.11 USD. Today WINT is down by -77.21%. In the past month the price decreased by -88.69%. In the past year, price decreased by -99.98%.
WINT Key Statistics
- Market Cap
- 3.226M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -400.00
- Dividend Yield
- N/A
WINT Stock Performance
WINT Stock Chart
WINT Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to WINT. When comparing the yearly performance of all stocks, WINT is a bad performer in the overall market: 99.81% of all stocks are doing better.
WINT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to WINT. WINT may be in some trouble as it scores bad on both profitability and health.
WINT Earnings
WINT Forecast & Estimates
6 analysts have analysed WINT and the average price target is 180.54 USD. This implies a price increase of 164027.27% is expected in the next year compared to the current price of 0.11.
WINT Groups
Sector & Classification
WINT Financial Highlights
Over the last trailing twelve months WINT reported a non-GAAP Earnings per Share(EPS) of -400. The EPS decreased by -236.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -77.52% | ||
| ROE | -183.17% | ||
| Debt/Equity | 0.01 |
WINT Ownership
WINT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.08 | 369.265B | ||
| AMGN | AMGEN INC | 15.25 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.89 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.72 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.43 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.91 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 10.97 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.8 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.46 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About WINT
Company Profile
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. The company is headquartered in Warrington, Pennsylvania and currently employs 14 full-time employees. The firm is engaged in the biotechnology business, advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. aPKCi inhibitor platform is a potential high-potency, specific, drug candidate with applications in oncology, particularly in hedgehog pathway-dependent cancers. The firm also has a licensing business model with partnership out-licenses in place. The firm is also focused on environmental services space.
Company Info
IPO: 1995-08-09
WINDTREE THERAPEUTICS INC
2600 Kelly Rd Ste 100
Warrington PENNSYLVANIA 18976 US
CEO: Craig E. Fraser
Employees: 14
Phone: 12154889300
WINDTREE THERAPEUTICS INC / WINT FAQ
Can you describe the business of WINDTREE THERAPEUTICS INC?
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. The company is headquartered in Warrington, Pennsylvania and currently employs 14 full-time employees. The firm is engaged in the biotechnology business, advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. aPKCi inhibitor platform is a potential high-potency, specific, drug candidate with applications in oncology, particularly in hedgehog pathway-dependent cancers. The firm also has a licensing business model with partnership out-licenses in place. The firm is also focused on environmental services space.
What is the current price of WINT stock?
The current stock price of WINT is 0.11 USD. The price decreased by -77.21% in the last trading session.
Does WINDTREE THERAPEUTICS INC pay dividends?
WINT does not pay a dividend.
What is the ChartMill technical and fundamental rating of WINT stock?
WINT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of WINDTREE THERAPEUTICS INC (WINT)?
WINDTREE THERAPEUTICS INC (WINT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-400).
Can you provide the upcoming earnings date for WINDTREE THERAPEUTICS INC?
WINDTREE THERAPEUTICS INC (WINT) will report earnings on 2025-11-24, after the market close.
Who owns WINDTREE THERAPEUTICS INC?
You can find the ownership structure of WINDTREE THERAPEUTICS INC (WINT) on the Ownership tab.